Effects of the Pharmabiotic U-21 under Conditions of a Combined Neuroinflammatory Model of Parkinson's Disease in Rats

Bull Exp Biol Med. 2024 Jun;177(2):225-230. doi: 10.1007/s10517-024-06161-5. Epub 2024 Aug 2.

Abstract

Data on the participation of microbiota in the development of Parkinson's disease allow us to discuss the ability of bacterial preparations to influence the processes leading to neurodegeneration. We studied the effect of oral administration of Limosilactobacillus fermentum U-21 lyophilisate on a model of Parkinson's disease in rats induced by combined intranigral injection of LPS and systemic administration of paraquat. The toxins significantly increased the number of missteps in the "narrowing beam walking" test, but a tendency to a decrease in this parameter was shown after treatment with U-21. It should be noted that U-21 did not reduce the neuronal death in the substantia nigra, but mitigated the inflammatory glial response, decreased the accumulation of phosphorylated α-synuclein and complement protein C3. Our study demonstrated the efficiency of the combined model of parkinsonism and reduction of proinflammatory changes under the influence of pharmabiotic without changes in the nigral neuronal death and motor deficits.

Keywords: Limosilactobacillus fermentum U-21; LPS; Parkinson’s disease; paraquat; pharmabiotic.

MeSH terms

  • Animals
  • Complement C3 / metabolism
  • Disease Models, Animal*
  • Lipopolysaccharides* / pharmacology
  • Lipopolysaccharides* / toxicity
  • Male
  • Neuroinflammatory Diseases / drug therapy
  • Neuroinflammatory Diseases / pathology
  • Paraquat
  • Parkinson Disease / drug therapy
  • Parkinson Disease / metabolism
  • Parkinson Disease / pathology
  • Rats
  • Rats, Wistar
  • Substantia Nigra* / drug effects
  • Substantia Nigra* / metabolism
  • Substantia Nigra* / pathology
  • alpha-Synuclein* / metabolism

Substances

  • alpha-Synuclein
  • Lipopolysaccharides
  • Paraquat
  • Complement C3